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Abstract: Saliva plays an important part in oral health maintenance, mastication, deglutition
and the start of the digestive process. It supports clear speech. Alterations to the composition
and flow of saliva through hyper- or hyposecretion or anterior loss through the lips thus have
potentially significant consequences. This article reviews the metrics, possible age and
gender differences and diurnal variability of flow in healthy individuals. It then focuses on
the ways in which this is altered in Parkinson’s disease (PD) and the possible mechanisms for
why people with PD drool. It reviews procedures for clinical assessment and management.
Many studies report drooling prevalence >50% of people with PD, though in the early stages
the impact may not yet be great. In PD, saliva flow is normal or even decreased compared to
people without PD. Motorically sialorrhea arises from an interaction between oro-facial
rigidity, lingual bradykinesia and aspects of oro-pharyngeal dysphagia. Postural, cognitive,
attentional and pharmacological factors may also contribute. Objective evaluation of sialor-
rhea looks at the rate and variability of flow (milliliters or milligrams per unit time; swallow
intervals; consistency). Since objective measures seldom reflect patient-reported lived experi-
ence, assessment includes rating scales that capture subjective concerns. Because altered
salivary function impacts on (peri)oral health, assessment and monitoring of this is strongly
advocated. Methods in each of these assessment domains are introduced. Clinical guidelines
recommend behavioral interventions in the first instance, with pharmacological treatments,
including botulinum injection, as follow-up possibilities. Surgical procedures are reserved for
severe or intractable cases. High-quality evidence for the efficacy of behavioral interventions
is lacking. Drug therapy efficacy is also under-studied, apart from botulinum toxin manage-
ment. Few studies have examined surgical interventions in PD, though principles are well
established from other populations. Strands of enquiry for improving our knowledge of
behavioral interventions are suggested.
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Introduction
Saliva plays a vital role in health and well-being. Impairment of production and/or
control of saliva may lead to a range of negative effects ranging from mild
annoyance at perceived lack or excess of saliva to major health and social issues.
Saliva control is affected by Parkinson’s disease (PD). Key guidelines for PD
management emphasize the importance of attending to saliva.1,2
The target readership of the review are people familiar with PD who are seeking
an up-to-date exposition of the issues and findings around sialorrhoea in people
with Parkinson’s. To set the context, the opening section summarizes some princi-
pal points around production and control of saliva in unaffected individuals and its
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role in health maintenance. It then examines recent litera-
ture on how PD disrupts this and possible health and
psycho-social consequences of overlooking changes.
Subsequent sections consider assessment of saliva flow,
with an emphasis on clinical methods. It concludes by
reviewing options for management, including behavioral,
pharmacological and surgical possibilities. Excessive sal-
iva flow is also termed sialorrhea, ptyalism or drooling.
These terms are used interchangeably in this article.
Difficulties with saliva control may lead to unintended
loss posteriorly into the pharynx and anteriorly from the
lips. The former has considerable implications in assess-
ment of swallowing, swallowing safety and airway health.3
Whilst posterior and anterior loss are not unrelated, the
focus here is on anterior loss.
Role of saliva in health andwell-being
Two primary functions of saliva concern its role in main-
taining oral pH and microbiotic homeostasis, and facilitat-
ing swallowing and speaking.4–6 Saliva possesses
antimicrobial, anti-viral and anti-fungal properties which
aid oral cleansing, protect against infection and support
tissue repair; it dilutes sugars and helps stabilize acidity; it
contributes to remineralization of dental enamel. It serves
as a buffer for extremes of temperature or against noxious
substances. It lubricates the oral cavity, thereby supporting
formation and transport of the bolus to the pharynx. It acts
as a first stage in digestion and stimulates interaction with
chemosensory receptors to aid taste and smell perception.
It supports smooth and accurate movement of the tongue
and lips for speech.
Healthy salivation
Healthy saliva flow produces around 0.75–1.5 liters per
day.4,5,7,8 Unstimulated (also called “resting state”) flow
estimates range around 0.10–2.9 mL/min.8,9 As the wide
estimates illustrate, there exists considerable inter- and
intra-individual variation. There is a circadian rhythm to
flow, peaking mid-late afternoon and lowest during
sleep.5,10,11 Flink et al10 showed significant increases in
flow between 07.30 and 11.30, with proportionately com-
parable increases in flow across subgroups defined as
having very low, low and normal flow rates. Using visual
analog scales to estimate subjective sensation of dry lips,
dry throat, ease of speaking and swallowing and saliva
consistency, the very low flow group showed significant
improvements between testing points, with smaller
changes for the low group and none for the “normal”
group. There is therefore a risk of misdiagnoses if testing
time variables and baseline status are ignored;10 Flink et
al recommended early morning testing as an optimally
informative time.
Secretion is heightened by stimulation (gustatory,
olfactory and possibly visual), with magnitude of
response decreasing across sour, salt, bitter, sweet,
umami/savory stimulants.5,12,13 Although the overall esti-
mate is 30% of secretion from the parotids, 60% from the
submandibular and 10% from the sublingual and minor
glands,4,5 a shift in contribution occurs between unstimu-
lated and stimulated mode. In unstimulated conditions, ca
65% of saliva secretion emanates from the submandibular
glands and is rich in mucin,5,12 which forms a viscoelas-
tic lubricating and protective covering for the oral
mucosa. In stimulated conditions, around 50% (higher
during mastication) of flow originates from the parotids,
leading to high concentrations of alpha-amylase (ptyalin)
and other enzymes with a function in decomposing
starches.
Possible gender differences in saliva production have
been debated. Males produce significantly greater flow.
Not all studies corroborate this.13,14 In other research,15,16
males produced significantly greater absolute volumes of
saliva, but once relative size of glands, body height and
body mass index/surface area were controlled, gender
differences disappeared. Hence, in judging normality indi-
viduals should be compared to data from the same
gender.15
Some studies claim decreases in flow with age.9,14
Others have not replicated these differences.13,17,18
Diminution with age of olfactory and gustatory sensitivity
may exercise some influence on stimulated flow. Age-
related tissue changes in the salivary glands may influence
mucin secretion.5,18,19 Also, secretion may be affected by
medications.20 Older people are more likely to be on long-
term (multi)drug regimes.12,21
Frequency of swallowing (and therefore clearing of
saliva) varies. Frequency is greatest during meals.6
Highest flow rates are associated with shortest swallowing
intervals.8 Least swallows occur during sleep. Twenty-four
hour total swallows is around mean 580, range 200–1000.7
Mean interval between swallows is around 60 secs but
with large ranges (9–200).8 During sleep, periods of
mean 30.3 mins without a swallow happen.7,11 Sleeping
deglutition frequency ranged between 2.1 and 9.1 swal-
lows per hour in ten adults, 20–25 years, with swallows
most prevalent in REM sleep.11
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Disruption to saliva flow in PD
Impaired flow or consistency of saliva exposes to risks of
lowered resistance to infection, depressed oral health,
impaired bolus formation and transportation and implications
for digestion. Consequences include dry mouth, ulceration,
tooth decay, gingivitis, candidiasis, halitosis and perioral
dermatological issues.12,19,22 Actual and perceived xerosto-
mia (sensation of dry mouth) or (sensation of) excess saliva
in the mouth can influence voice quality and intelligibility
beyond problems that stem from the underlying PD.
Hyposalivation linked to medication or dysautonomia,12,20
or loss of saliva through drooling can affect bolus formation
and exacerbate an already compromised swallowing
mechanism. As the secondary effects from drooling (eg
odor, stained clothes, constant wiping) are socially undesir-
able in many societies, presence of sialorrhea may bring
repercussions for psycho-social health of the person who
drools and added burden for the carer (eg washing clothes;
restricted social life).
Prevalence figures suggest ca 10–70% of people with
PD are affected by drooling,23–32 with no significant var-
iation across ethnic groups.33 In investigations that report
control data, drooling occurred in ca 6–15% of people
unaffected by PD.25,28,30,34 Divergences in estimations
reflect composition of populations studied, assessment
methods and condition (stimulated or/and unstimulated
condition), patient vs clinician evaluation, as well as
examination time (of day; in progression of PD).35
In an analysis of autonomic and sensory symptoms in
207 people with very early and untreated PD,25 42%
recorded drooling, but for 90%, the influence of all auto-
nomic dysfunction symptoms was only mild. In another,30
drooling occurred in 50% of 119 people at early stage PD;
37% felt it a significant problem. Kalf et al26 evaluated
104 pwPD (person/people with PD) and found 71%
drooled – 43% with a sensation of excessive saliva or
night time drooling (“pre-droolers”) and 28% who drooled
through the day (only two were observed drooling at
examination). Impact was greater with more advanced
PD. Feresttehnejad et al31 found significant drooling for
only 11.7% of 314 people with PD at or around initial
referral. This proportion rose to 55.3% at approximately 4-
year follow-up, demonstrating the likelihood that drooling
becomes a significant problem if left unchecked.
People with PD often report xerostomia. Some medica-
tions influence actual and perceived dryness.20,21,36
Anterior saliva loss can be a contributory factor. The
relationship between dysphagia, drooling and xerostomia,
though often observed, is complex.22,37–39 Barbe et al19
ascertained subjective dysphagia was associated with
drooling and xerostomia, but drooling prevalence or inten-
sity did not influence xerostomia symptoms. Xerostomia
peaked at 09.00 and 21.00 but there appeared no signifi-
cant association of this with drooling intensity levels.
Drooling can impact quality of life for pwPD and
carers.22–24,28,40–42 Karakoc et al43 reported drooling in
65% of 63 people with PD, but no independent significant
correlation of drooling severity with quality of life.
However, they measured the latter from the total PDQ-39
score,44 rather than with a tool that measures drooling
impact. Further, 89% of their cohort evidenced only
night-time symptoms when one might expect little psycho-
social impact.
Mechanisms for drooling
disturbance in PD
Patient reports of “too much saliva in my mouth” suggest
hypersalivation as a cause. However, saliva production
appears unchanged or even depressed in PD, indicating
excessive salivation is not a crucial factor.26,38–40,45–47
Decreased salivary flow may relate to dysautonomia in
PD. Hyposecretion may arise from medications common in
PD.20,21,36 Altered reaction to stimulation, from reduced
olfactory and other sensory triggers, may also play a role.48
Hou et al49 conducted a fMRI investigation to examine
basal ganglia functional connectivity in drug-naïve people
with PD who did or did not drool. Those with sialorrhea
showed significantly reduced functional connectivity of
putamen within bilateral sensorimotor cortices, superior
and inferior parietal lobules and areas in the right occipital
and temporal lobes.
Risk factors for drooling in PD
If susceptibility to anterior drooling is not related to hypersa-
livation, other factors must be at work. Suggested candidates
have been dysphagia, oro-facial rigidity/hypomimia, lingual
bradykinesia, cognitive status, male gender and more
advanced disease stage.23,24,28,31,39,43,50,51 Individuals with
non-tremor dominant PD phenotypes were at higher risk of
drooling.31,52 The precise contribution of these factors
remains unsettled. The uncertainty rests partly on general
issues above regarding why estimates of drooling prevalence
and flow rates exist, but variability in individual profiles of
impairment and disability also contributes.
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Susceptibility of males probably relates to greater
absolute flow rate when body mass and gland sizes are
not controlled for – though not all studies have found a
male predominance.23,24,29 Relationship to greater disease
severity likely reflects increased rigidity, poorer cognitive
status and more marked dysphagia of later stages, and, in
as far as medications may alter the picture, higher medica-
tion dependency.21
Dysphagia in PD arises from a range of factors.3 Those
most pertinent to anterior drooling relate to reduced tongue
motility and depressed initiation of swallow reflexes. This
leads to failure to swallow saliva regularly and/or efficiently,
leaving excess saliva in the mouth and the (mistaken) impres-
sion of hypersalivation. However, as noted above, whilst some
have noted a strong association of dysphagia with sialorrhea
others found the relationship not so straightforward.
Facial muscle rigidity can impair lip control and
depress swallowing efficiency, as well as render indivi-
duals prone to anterior loss of saliva.31,39 Any combination
of stooped body posture, flexed neck and open lips/low-
ered mandible may aggravate attempts to retain saliva in
the mouth, hinder directing saliva posteriorly and reduce
the likelihood of initiating a swallow reflex. Germane to
this, there was greater propensity for drooling in pwPD
and camptocormia.53
Cognitive impairment can influence drooling likeli-
hood and severity.30,50 The relationship may not be
directly with cognitive status so much as associated
changes to attention, especially during competing or dual
task situations.54 Reynolds et al55 measured drooling
severity and frequency at rest and during a distracting
computer task in 18 people with PD reporting day-time
drooling. There was no significant difference between
drooling severity at rest and during distraction, but parti-
cipants swallowed significantly less frequently and drooled
significantly more often during the distraction task.
The question of possible consequences of l-dopa medica-
tion and deep brain stimulation (DBS) for drooling arises in
PD. The effects of l-dopa (negative or positive) on sialor-
rhoea remain unclear. The question has not been a prime
focus of investigations, so inferences are indirect at best.
Drooling is linked to higher l-dopa daily dosage equivalents
(LDDE),23,24 but this likely reflects greater prevalence of
drooling in more severe PD of greater duration. When
motor, age and duration variables are controlled, LDDE
appears no longer associated with drooling severity.23,24,52
Proulx et al38 found an association of l-dopa and hyposaliva-
tion, but Persson et al56 observed no differences in salivary
secretion rate between pwPD and controls, nor between
subgroups of pwPD taking versus not taking dopaminergic
medication. Bagheri et al45 established no difference in sali-
vary flow rates between treated and de novo pwPD. Barbe
et al19 linked higher LDDE to drier mouth. In so far as
dopamine modulates salivary secretion,57 an association of
LDDE and drooling might be expected, but clear causal
evidence in humans is lacking.
L-dopa can influence variables in swallowing
efficiency,3,58 and thus indirectly change drooling.
Currently, dysphagia study outcomes do not afford suffi-
cient evidence to conclude a positive, neutral or negative
effect of possible swallowing changes on sialorrhoea.
Similar conclusions apply to the effects of DBS in PD.
No studies have tested drooling directly. In one study,
increased drooling was an adverse effect of DBS reported
by one of 18 patients.59 Positive, neutral and negative influ-
ences of DBS on aspects of swallowing are reported,3,60–63
which potentially could have repercussions for drooling.
However, in the absence of direct data pertaining to impacts
on sialorrhoea, the issue remains open.
Assessment of saliva flow
Evaluation of saliva flow is challenged by a range of issues,
including: difficulty obtaining objective measures in natur-
alistic settings (though64 found no differences in unstimu-
lated flow rate between laboratory and clinic settings); time
and place variability that exists in respect of natural varia-
tion in flow rates; fluctuations in motor function experi-
enced by pwPD that can impact on swallowing and saliva
control; the variety of situations across pwPD concerning
where they experience difficulties or not; and the subjective
nature of whether an individual perceives there to be a
problem present or not. Similar to other activity limitations
in PD such as dysphagia and dysarthria, perceived magni-
tude of psychosocial impact of drooling, dry mouth and
excess saliva does not necessarily correlate significantly
with objective measures of saliva flow and loss.3,19,65–67
These factors underline that no single assessment cap-
tures all dimensions important for establishing baseline and
outcome measures of salivation/drooling. Accordingly, out-
come evaluation covers a range of measurements, with a
focus on key variables that encompass the patient’s own
chosen concerns and goals.
Objective measures of flow/volume
Objective measurements of milliliters or milligrams secre-
tion per minute typically center around gathering saliva at
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regular intervals over given time periods.68,69 Sampling
methods include collecting saliva from cups placed over
salivary ducts, expectoration into pots or tubes, weighing
of gauze or cotton rolls held at given loci in the mouth, use
of centrifuges to extract saliva from the gauze to quantify
the volume of saliva absorbed or allowing saliva to dribble
from the mouth with the head held forwards over
receptacles.
As secretion is sensitive to a number of influences,
gathering ideally occurs under controlled conditions.
Posture is controlled; the environment is quiet, with
absence or minimization of visual, olfactory or gustatory
stimuli known to prompt increased flow. Comparability of
stimulated flow across patients and time demands use of
standard stimulatory material and doses (eg citric acid
volume and concentration; gum consistency and flavor
control for chewing). To assure inter- and intra-individual
comparability, evaluations ideally happen at the same time
of day; at the same point in the drug cycle (or with patients
in a pragmatically defined off state); in the same relation-
ship to meal times (eg 2 hrs absence of eating before
testing, in the morning having fasted overnight). On–off
status and fluctuations need to be monitored as well as
presence and severity of dyskinesias that may affect
measurements.70
Van Hulst et al71 devised a drooling severity quo-
tient to assess severity in children with cerebral palsy
that could be adapted to people with PD. Before obser-
vations began, all food was cleared from the child’s
mouth and the lips and chin wiped clean. Appearance
of a new drop or string of saliva at the lips was
counted as a drooling event. The presence or absence
of drooling was recorded by the observer at 15-second
intervals across 10 mins of observation. The drooling
quotient is the number of drooling events observed
expressed as a percentage of total observation points.
Since saliva volume may be influenced by swallowing
behavior, saliva measures can be gainfully supplemen-
ted by parallel swallow frequency metrics – eg from
live visual counts or palpation of larynx raising asso-
ciated with swallows, or counts based on accelerometer
detected movements or swallow sound acoustics.72
The time costs involved probably preclude above
methods representing routine clinical procedures. They
are more aptly confined to research investigations or indi-
vidual cases that strongly warrant such investment of time
and effort. Day-to-day clinical practice is more likely to
rely on rating scales.
Rating scales
Many tools are unstandardized and unvalidated scales
restricted to use in one center. Some are scales developed
for any etiology of (suspected) drooling, acquired or
developmental. The number that have undergone psycho-
metric evaluation is low; those devised or adapted specifi-
cally for PD even lower.
One partially validated tool is the Sialorrhea Clinical Scale
for PD (SCS-PD).73 It has seven items employing 4-point
ordinal rating scales for the pwPD to determine their impres-
sion of drooling over the previous week. Items cover severity
and frequency when asleep and awake, impact in relation to
speaking and eating, and impact on social situations.
The Radboud Oral Motor Inventory for PD subscale
for saliva (ROMP-S)74 is the only other tool currently
validated on pwPD. It is derived from the unvalidated
Drooling Frequency and Severity Scale (DFSS),75 origin-
ally drawn up for children with cerebral palsy, but
employed in several other populations. It was slightly
modified for ROMP-S, in particular by adding the option
to score that one is troubled by (perceived) accumulation
of saliva without actually drooling. The nine items, rated
on 5-point ordinal scales, cover day and night-time fre-
quency and severity, effects on speech and eating and
drinking, how frequently one has to wipe away saliva,
limitations on daily activity and social participation and
overall impact.
Reid et al (2009)76 devised and produced a psycho-
metric validation of a tool to evaluate the impact of drool-
ing in children with developmental disability, which shows
potential for adaptation to people with PD. The child
version uses 10-point equal appearing interval scales to
chart overall severity, frequency and disruption in relation
to need to wipe the face/furniture/toys and wash clothes,
effects on perioral skin, embarrassment socially and in
relation to smell of the saliva, and impact on the child
and their family.
Another approach entails diaries completed at spe-
cific times/places over given periods by the pwPD to
look at severity and frequency of symptoms and other
variables of importance to them. Hauser et al (2004)77
validated this method in relation to effects of motor
fluctuations and dyskinesias but the technique has been
used with other symptoms, including drooling.78 Diary
information is supplemented with five questions
related to symptoms of interest, scored on visual ana-
log scales.
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Some studies have employed the drooling item in
UPDRS II.79 This has been criticized as a coarse scale:
suggested severity levels are not spread evenly across
scale-points; while it is presented as an ordinal progres-
sion, the combination of asking about three variables that
may vary independently of one another (perceived amount
of saliva in mouth; night-time drooling; daytime drooling)
makes it difficult to classify responses accurately. The
UPDRS sub-scales on facial rigidity/lip opening and
motor fluctuations and their impact may provide useful
supplementary diagnostic information.
The Movement Disorder Society reviewed dysautono-
mia rating scales pertinent to PD,80 including for sialorrhea.
They recommended further psychometric work on visual
analog scales and classed the SCS-PD,73 as a suggested tool
pending further validation. ROMP-S74 was unavailable at
the time. They considered two broader scales – the
Nonmotor Symptom Assessment Scale, Non-motor
Symptoms Questionnaire,81 and the Scales for Outcomes
in PD-Autonomic,82 as suitable for recording presence–
absence of sialorrhea but not finer quantification.
Measurement of related variables
In as far as ptyalism in PD may be linked to other symp-
toms, other assessments may be pertinent to place real and
perceived drooling in its broader context. These cover
assessment of swallowing, speech and voice.3,65 Detailed
dental examination and monitoring of oral health may be
indicated for some individuals, over and above routine
dental supervision.22,83
People with PDmay experience dry mouth/xerostomia.21
Perceived dryness does not necessarily reflect objective
levels of dryness defined by salivary flow rate/volume,
mucosal wetness and saliva consistency.84 The Clinical
Oral Dryness Score (CODS)85 is a validated clinician-admi-
nistered semi-quantitative tool. The score comes from obser-
ving the presence/absence of ten symptoms and signs
characteristic of dry mouth. It is combined with a 0–10 rating
by the patient on how far they are bothered by xerostomia.
Perceived impact has also been gauged using five questions
related to possible activity and participation restrictions com-
monly reported by people with xerostomia.85
The PDQ3944 contains items on avoiding eating and
drinking in public and speech/communication problems,
but has nothing specific to drooling, despite several studies
employing it as a sialorrhea rehabilitation outcome measure.
Drooling does not easily lend itself to blanket rating
scales or general questions. Some tools above include
subscales that endeavor to capture situational variability
in severity, frequency and impact. When and where drool-
ing poses a problem for pwPD can be highly individual,
related to their lifestyle and own perceived impact of
saliva loss. To deliver tailored support case history taking
can extend rating scales by identifying times and places
where the person considers drooling exercises a strong
impact. This can lead to evaluation of what contributors
to impact appear particularly pertinent to the circum-
stances – eg (attention to) posture, fatigue, cognition, dur-
ing or soon after meal times, in relation to speaking, eating
in public. This in turn facilitates targeted intervention
activities that address the main concerns of the individual.
It also enables specific goal-oriented outcome measures to
monitor clinical and social success.
Management of saliva flow
The British NICE (National Institute for Health and Care
Excellence) guidelines for PD2 recommend referral to a
speech-language clinician for assessment and treatment of
drooling, though overall management is multidisciplinary.
The guidelines advocate behavioral methods of interven-
tion in the first instance, followed by consideration of
pharmacological or surgical options if/when these are
ineffective.
Behavioral
Behavioral interventions seek compensatory strategies to
minimize or remove the problem with drooling and/or
entail more active intervention to modify what appears to
be the culprit underlying dysfunction, such as reduced
swallowing frequency or efficiency, or oro-facial rigidity.
Attention to posture is a frequently employed compen-
satory route. Intervention aims to achieve and maintain a
head and trunk position that minimizes or prevents anterior
saliva loss. If assessment has identified key contexts where
drooling is most bothersome – eg rising from a chair,
reading, working at the computer, eating, lying down –
then focusing on strategies that work for those circum-
stances should arguably be more successful than general
(re)training of posture. Management may couple posture
procedures with other strategies, such as remembering to
swallow as much saliva as possible before attempting to
rise from the chair, avoiding particular foodstuffs at certain
times, raising the eyelevel of reading material or computer
screen. Having prompt words/signals that companions use
to discreetly remind the pwPD to apply their strategy in
target situations is a common addendum.
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If ptyalism is linked to (especially oral phase) dyspha-
gia, then therapies that foster safer and more efficient
swallowing should potentially result in less saliva loss.
Few dysphagia interventions have been tested out on
pwPD,3 and have generally neglected drooling changes
in favor of measuring swallow safety and airway health.
Hence, further work is awaited regarding the logic of
applying swallowing therapy to alleviate drooling in PD.
Several dysphagia therapies involve oro-facial exercises
aimed at better bolus management and initiation of pat-
terned swallow reflexes, whilst other therapies have sought
to counteract hypomimia.3,86–89 If oro-facial rigidity con-
tributes to anterior saliva loss and these techniques improve
oro-facial control, then drooling should be ameliorated. To
date, no large-scale treatment trials have examined this.
If the problem with drooling is not so much the inabil-
ity of the person to swallow voluntary and safely but the
frequency with which saliva is cleared, methods to cue the
person to swallow at regular intervals may be effective.
Preliminary demonstrations of this principle exist.78,90
Initial studies employed auditory cues. These may not be
the most favorable – the person with PD may not hear
them and they may attract unwanted attention of others in
the environment. To circumvent this, others have
employed tactile cues. In a proof of concept and feasibility
pilot,78 employing a wrist-worn tactile cue to increase
swallowing regularity twenty-two from twenty-eight parti-
cipants found positive benefits, with significant overall
group differences on visual analog scale self-rating of
drooling frequency and severity pre-post the 4-week inter-
vention. Early indications are that devices prove highly
successful for many people with PD, but not everyone.
Longer term follow-up has not yet been detailed. Future
work is required to test out on larger populations which
person, situation, cue type and frequency variables lead to
more successful outcomes.
Since drooling and dysphagia are linked to poorer oral
hygiene, management should encompass daily care rou-
tines and regular dentist supervision.22,83 For pwPD who
experience dry mouth, artificial saliva products are
available.91–93 Whilst largely successful in ameliorating
certain aspects of real and perceived dry mouth, they are
not substitutes for all the roles of saliva. Many efficacy
studies have been criticized for the level of (potential)
commercial bias involved. The specific needs of pwPD
have not been a focus. Firmer indications for short- and
long-term xerostomia management for pwPD is therefore
needed.
Use of gum, salivation stimulus strips and saliva sti-
mulation agents21,94,95 have been suggested as means to
overcome xerostomia. However, whether they might
thereby exacerbate perceptions of over-accumulated saliva
has not been investigated, and risks of increased dental
caries arise with some agents.
Pharmacological
A range of pharmacological interventions have been used
to treat drooling in pwPD.21,57,96 Anticholinergic drugs
block cholinergic receptors, thereby depressing salivary
secretion. Botulinum toxin inhibits acetylcholine release,
in turn leading to hyposecretion of saliva by inhibiting
cholinergic parasympathetic and postganglionic sympa-
thetic activity. Both avenues can be contraindicated if
there is already significant dry mouth.
The British PD NICE guidelines 20172 recommend
consideration of pharmacological management for drool-
ing only if non-pharmacological management is unavail-
able or has been ineffective. The anticholinergic
glycopyrrolate bromide is considered first line. If this is
ineffective, not tolerated or contraindicated, referral to a
specialist service for botulinum toxin A* is an option.
Anticholinergic medicines other than glycopyrrolate bro-
mide should only be applied if the person’s risk of cogni-
tive adverse effects is thought to be minimal.
Glycopyrronium was effective in a small (n 23) rando-
mized control trial in PD,97 with no evidence that it worsened
motor symptoms. It shows fewer central nervous system
side-effects than other anticholinergics as it is not centrally
acting. It should be used with care in pwPD with significant
cognitive decline, or who experience hallucinations. It is
poorly absorbed and therefore has relatively few systemic
side-effects, but these can include bladder outflow obstruc-
tion, cough, nausea, headache and dizziness. Glycopyrrolate
should be given as 1-2 mg 2 or 3 times daily orally. Other
anticholinergic medicines are only considered if there are no
concerns about potential cognitive side-effects.
Sublingual atropine was used in an open-labeled pilot
study in 6 pwPD and 1 progressive supranuclear palsy
patient with drooling at a dose of 1 drop of 1% atropine
solution twice daily for 1 week.98 It reduced salivary
production, measured objectively and subjectively, but
one patient experienced delirium and two experienced
hallucinations. In a study with 17 pwPD with drooling,99
there was no significant difference in objective measures
after two weeks when comparing Ipratropium bromide to
placebo, but there was a mild subjective improvement in
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the Ipratropium group and no significant differences in
adverse events. However, there was insufficient evidence
on safety and efficacy to recommend Ipratropium bromide
spray for the treatment of drooling in PD.96 Systematic
reviews57,100 have reported Clonidine to significantly
improve long term the number of times that saliva had to
be cleared from the mouth, and Modafinil, an α-1 receptor
agonist, has been reported to improve drooling most likely
by improving dysphagia.
Botulinum toxin (BoNT) is recognized as beneficial for
drooling control in the majority of pwPD, with relative
lack of adverse side-effects.101,102 Of existing subtypes,
Botulinum toxin A and B (BoNT-A and BoNT-B) are most
common in PD, with BoNT-A more widespread. All ther-
apeutic doses of BoNT are considered safe for manage-
ment of drooling in PD, with evidence for the efficacy of
ona-A; abo-A, inco-A and BoNT-B.103–110
Which formulation to choose varies.111,112 Evidence
for abo-A, ona-A and Rima-B to manage drooling in PD
is stronger, with lower level recommendation for inco-A,
mainly due to lack of strong research evidence.112 Inco-A
has the advantage that, unlike some other formulations, it
can be stored at room temperature making it more suited
for community care settings.
Dosage of BoNT varies by subtype involved, with a
lack of agreement on the optimum dosage.101,113 Lack of
effect of some formulations has been attributed to the low
dosage employed rather than the formulation itself.114
Further research is needed on this. Therapeutic effects of
BoNT commonly appear within a week after injection,
although there is variability. Effects are temporary, lasting
from ca 2.5–5 months before further injections are
required.
BoNT is usually injected into the parotid or subman-
dibular glands or both. Studies differ as to whether uni-
lateral or bilateral injections prove more effective.
Injection site is typically located by using ultrasound,
electromyography or by manual palpation of the gland.
Many clinicians suggest ultrasound guidance is essential
for locating precise injection site, giving lower risk of
adverse events, but there remains no clear consensus on
this.102,106,113 A risk is that BoNT diffuses into surround-
ing muscles and soft tissue resulting in muscle weakness
and possible (increased) dysarthria, dysphagia and/or mas-
tication difficulty.103,110,115 Therefore, techniques that
increase injection accuracy are important. Other possible
side-effects include xerostomia, thickening of saliva,
diarrhea, gait disturbance, neck pain and an increased
risk of poor oral hygiene.101,107,108,116
Despite widespread use, there exists a lack of clear
consensus on the safest and most effective formulation,
dosage and method of treatment.21,113 Clinical guidelines
or recommendations specific to BoNT for drooling in PD
are not definitively established. As a result, clinicians
working with pwPD continue to encounter difficulty deter-
mining the candidacy, efficacy and safety of BoNT in this
context.
Surgical
Following NICE Guidelines,2 surgical interventions are
reserved for cases where other approaches proved unsuc-
cessful or are no longer effective (eg resistance to phar-
macological agents developed; too severe to overcome by
behavioral compensation). Several surgical procedures
are available, alone or in combination, uni- or bilaterally
applied. These include radiotherapy, neurectomy, salivary
gland excision, duct ligation and duct rerouting or reloca-
tion. None is 100% successful for all pwPD. Options
present a range of possible adverse effects, covering
harmful radiation exposure, short or long-term toxicity,
more severe xerostomia, impact on swallowing, loss of
taste perception and hearing loss (when neurectomy
involves the chorda tympani nerve). Trials have predo-
minantly involved children with cerebral palsy, with
fewer studies directed at adults.117–119 Very few specifi-
cally involve pwPD.120 Consideration for surgery and
choice of technique remains a highly individualized
case by case affair.
Conclusion
Sialorrhea is a frequent in pwPD.Whilst formost individuals it
may not exercise a perceived impact comparable to other
features of motor and non-motor change in PD, especially in
the early stages, for those who are affected it represents a
challenging and distressing symptom. Even when drooling
does not unduly bother the individual, its potential conse-
quences for swallowing, speech, oral and general health
mean it should be attended to as a strategy to prevent other
possible complications. Interventions are available but there
remains a serious need formore definitive studies, especially in
relation to pwPD.
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